$0.99
4.35% today
Nasdaq, Apr 03, 06:42 pm CET
ISIN
US02262M3088
Symbol
ALZN
Sector
Industry

Alzamend Neuro Inc Stock price

$1.04
+0.28 37.64% 1M
-0.63 37.72% 6M
-0.12 10.34% YTD
-8.05 88.56% 1Y
-178.96 99.42% 3Y
-2,023.96 99.95% 5Y
-2,023.96 99.95% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.04 4.51%
ISIN
US02262M3088
Symbol
ALZN
Sector
Industry

Key metrics

Market capitalization $6.87m
Enterprise Value $3.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.75
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-4.21m
Free Cash Flow (TTM) Free Cash Flow $-7.40m
Cash position $3.36m
EPS (TTM) EPS $-3.06
P/E forward negative
Short interest 1.89%
Show more

Is Alzamend Neuro Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Alzamend Neuro Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Alzamend Neuro Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Alzamend Neuro Inc forecast:

Buy
50%
Hold
50%

Financial data from Alzamend Neuro Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
- -
-
100%
- Direct Costs 0.05 0.05
25% 25%
-
-0.05 -0.05
25% 25%
-
- Selling and Administrative Expenses 2.96 2.96
33% 33%
-
- Research and Development Expense 1.15 1.15
85% 85%
-
-4.16 -4.16
66% 66%
-
- Depreciation and Amortization 0.05 0.05
25% 25%
-
EBIT (Operating Income) EBIT -4.21 -4.21
66% 66%
-
Net Profit -4.23 -4.23
66% 66%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alzamend Neuro Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alzamend Neuro Inc Stock News

Neutral
GlobeNewsWire
9 days ago
ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated ph...
Neutral
GlobeNewsWire
16 days ago
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital
Neutral
GlobeNewsWire
23 days ago
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated ph...
More Alzamend Neuro Inc News

Company Profile

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Tampa, FL.

Head office United States
CEO Stephan Jackman
Employees 7
Founded 2016
Website www.alzamend.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today